The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
New guidance coming soon!
-
Coming soon!! New guidance from PAAB stemming from our global benchmarking initiative.
@Agency @Manufacturer The consultation process for guidance on clinical trials whose duration exceeds that of the pivotal trials in the TMA is winding down. Please stay tuned for the publication of the guidance later this month with projected implementation in April.
We look forward to answering all your questions once we’ve published a guidance.
